Published 4 months ago • loading... • Updated 4 months ago

The biggest biotech news stories from the weekend

The Trump administration announced significant cuts to NIH grants supporting indirect costs and diversity in biomedical research, raising concerns among scientists.
Biotech companies like Absci and Generate:Biomedicines claim to create new antibody drugs using AI, but they often optimize existing ones instead, according to a STAT report.
Experts worry that budget cuts and political interference could threaten vital genetic databases, which are crucial for global biomedical research.
Critics argue that limiting funding and diversity in research will hinder scientific progress and exacerbate disparities in science funding.

Insights by Ground AI

Does this summary seem wrong?

2 Articles

All

Left

Center

Right

STAT

Center

Two biotechs say they're using AI to conjure drugs from scratch. Their documents suggest otherwise

AI drug discovery claims face scrutiny. Are Absci and Generate Biomedicines truly innovating, or is it biotech hype? Can AI build a drug from scratch?

4 months ago·Boston, United States

Read Full Article

ramaonhealthcare.com

STAT+: Two biotechs say they’re using AI to conjure drugs from scratch. Their documents suggest otherwise – RamaOnHealthcare

Experts are skeptical of the grand claims of startups like Absci and Generate BiomedicinesIt was January 2023. Elon Musk owned Twitter, but it wasn’t yet

4 months ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right